Join the Fight Against MDS
Every gift helps patients, caregivers, and healthcare professionals access life-saving resources, support, and education. Together, we can make a difference. Even a small contribution can create a big impact. Thank you for your generosity.
About This Webinar
This webinar, hosted by the MDS Foundation, will cover the topic of disease-related fatigue, with key discussion points including:
- Disease-related fatigue in MDS
- Disease-related fatigue in MPN
- Overview of the Global MPN Scientific Foundation
Simultaneous Spanish translation will be provided
Our featured speakers will include:
Rafael Bejar, MD, PhD: Dr. Bejar is a Professor of Clinical Medicine at the UC San Diego Moores Cancer Center where he directs the Myelodysplastic Syndrome (MDS) Center of Excellence. In addition to caring for patients, Dr. Bejar conducts laboratory research exploring the clinical impact of genetic mutations and epigenetic alterations observed in MDS. As of January 2020, Dr. Bejar has taken a partial leave to serve as the Chief Medical Officer for Aptose Biosciences, a pharmaceutical company developing drugs to treat hematologic malignancies. Dr. Bejar is a member of the International Working Group for MDS Molecular Prognosis Committee and the WHO Classification Committee. He is on the steering committee for the National MDS Study and serves on the Medical & Scientific Advisory Board of the MDS Foundation.
Marina Kremyanskaya, MD, PhD: Dr. Kremyanskaya is an Associate Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. She serves as the medical director for the inpatient oncology unit at The Mount Sinai Hospital, where she provides medical oversight in the management of hospitalized cancer patients. Dr. Kremyanskaya’s clinical focus is on myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML) and other myeloid malignancies such as myelodysplastic syndromes (MDS), chronic myeloid leukemia (CML), and other blood cancers.
She works as a part of a multidisciplinary team to provide high quality, patient-centered care and to ensure the best possible outcomes. Dr. Kremyanskaya is actively involved in the development of novel therapies for patients with MPN and AML, and is leading numerous clinical trials investigating better treatment options for these relatively rare conditions. She has authored multiple peer-reviewed publications and book chapters.
They will be joined by Peter Löffelhardt, Founder and CEO of the Global MPN Scientific Foundation.
Speakers
Rafael Bejar, MD, PhD
Marina Kremyanskaya, MD, PhD
